FibroGen to Report Second Quarter 2020 Financial Results

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) is set to announce its Q2 2020 financial results on August 6, after market close. A conference call for investors will follow at 5:00 p.m. ET to discuss the company's financial performance. FibroGen is recognized for its innovative therapies, notably roxadustat for treating anemia related to chronic kidney disease and other conditions. The company is also developing pamrevlumab for multiple serious diseases, including idiopathic pulmonary fibrosis and pancreatic cancer.

Positive

• Upcoming Q2 2020 earnings announcement on August 6, potentially revealing positive financial performance.
• Strong pipeline with roxadustat and pamrevlumab targeting unmet medical needs.

Negative

• None.

SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Dial-In Information
Live (U.S./Canada): (877) 658-9081
Live (International): (602) 563-8732
Confirmation number: 8363719

A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 8363719.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Media Inquiries:
Sara Iacovino
1.703.474.4452
sara.iacovino@gcihealth.com

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

FAQ

When will FibroGen announce its Q2 2020 financial results?

FibroGen will announce its Q2 2020 financial results on August 6, 2020, after market close.

What time is the FibroGen conference call?

The FibroGen conference call is scheduled for August 6, 2020, at 5:00 p.m. ET.

How can I access the FibroGen conference call?

You can access the live audio webcast of the FibroGen conference call via their website.

What is roxadustat developed by FibroGen used for?

Roxadustat is developed for treating anemia associated with chronic kidney disease.

What other diseases is FibroGen targeting with its pipeline?

FibroGen is also developing pamrevlumab for idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy.